Innovating Works

INSTITUT CATALA D'ONCOLOGIA

Activa
Mostrando 1 al 20 de 21 resultados
DEFINITIVE: Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA tramitó un HORIZON EUROPE: HER2+ breast cancer affects around 390.000 women annually worldwide (i.e. 3 patients every 4 minutes). Over the last decade, polychemotherapy and HER2-targeted therapies have improved patient´s surviv...
2023-12-11 | Financiado
PREVENTABLE: CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO tramitó un HORIZON EUROPE: Rare tumour risk syndromes (RTRS) are rare diseases, affecting 5 per 10.000 people or less and caused by heritable genetic variants. In RTRS, the lifetime risk to develop various cancers can be as hig...
2022-12-02 | Financiado
EUREST-RISE: European Regulatory Science on Tobacco - Research and Innovation Staff Exchange EUROPEAN NETWORK FOR SMOKING PREVENTION tramitó un H2020: Smoking and other forms of tobacco consumption are considered the single most important cause of preventable morbidity and premature mortality worldwide. Tobacco product design and additives provide a...
2021-06-01 | Financiado
RISCC: RISK-BASED SCREENING FOR CERVICAL CANCER STICHTING VUMC tramitó un H2020: Screening for cervical cancer is a globally recommended public health policy. Many risk factors are known, but so far only one-size-fits-all screening programs have been implemented, providing subopti...
2020-01-01 | Financiado
oncNGS: NGS diagnostics in 21st century oncology: the best, for all, at all times SCIENSANO tramitó un H2020: OncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients. The challenge will consist in prov...
2020-01-01 | Financiado
4-IN THE LUNG RUN: 4-IN THE LUNG RUN: towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM tramitó un H2020: With 338,000 EU-deaths annually, lung cancer is a devastating problem. CT screening has the potential to prevent ten-thousands of lung cancer deaths annually. The positive results of the Dutch-Belgian...
2020-01-01 | Financiado
ECT2019-000624: Horizonte Innovación en el ICO: Fortalecimiento de la Competitividad y del Liderazgo en Proyectos Europeos INSTITUT CATALA D'ONCOLOGIA tramitó un AEI: El proyecto INNOVICO ha sido concebido para cumplir con los objetivos estratégicos del ICO orientados al fortalecimiento de la investigación y la innovación: participar en proyectos internacionales, m...
2019-01-01 | Financiado
EUCANCan: EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine. BARCELONA SUPERCOMPUTING CENTERCENTRO NACIONAL DE SUPERCOMPUTACION tramitó un H2020: We propose to create the EUropean-CANadian Cancer network (EUCANCan), a federated infrastructure whose mission is to enable Personalized Medicine in Oncology by promoting the generation and sharing of...
2019-01-01 | Financiado
EDIReX: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts UNIVERSITA DEGLI STUDI DI TORINO tramitó un H2020: Counteracting high attrition rates in oncology drug development and providing optimal therapeutic management of cancer patients require preclinical models that properly recapitulate the complexity and...
2018-02-01 | Financiado
MEDIRAD: Implications of Medical Low Dose Radiation Exposure EIBIR GEMEINNUTZIGE GMBH ZUR FORDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG tramitó un FP6: MEDIRAD aims to enhance the scientific bases and clinical practice of radiation protection (RP) in the medical field and thereby addresses the need to understand and evaluate the health effects of low...
2017-06-01 | Financiado
AngioResist: Coordinated Development of Inhibitors and Biomarkers for Resistance to Antiangiogenics in Cancer - AngioResist INSTITUT CATALA D'ONCOLOGIA tramitó un FP7: Many anti-angiogenic drugs are clinically used in several types of cancer to block angiogenesis, impair tumor growth, progression and dissemination. Nevertheless, clinical trials report emergence of r...
2016-09-01 | Financiado
ANTI-SUPERBUGS PCP: ANTI-SUPERBUGS Precommercial procurement AGENCIA DE QUALITAT I AVALUACIO SANITARIES DE CATALUNYA tramitó un H2020: Infections caused by resistant microorganisms often fail to respond to the standard treatment, resulting in prolonged hospital stays, higher health care expenditures, and a greater risk of death.1 Ant...
2016-09-01 | Financiado
EUREST-PLUS: European Regulatory Science on Tobacco:Policy implementation to reduce lung diseases EUROPEAN NETWORK FOR SMOKING PREVENTION tramitó un H2020: Smoking and other forms of tobacco consumption are considered the single most important cause of preventable morbidity and premature mortality worldwide. Efforts to reduce the devastation of tobacco-r...
2016-01-01 | Financiado
TackSHS: Tackling secondhand tobacco smoke and e-cigarette emissions: exposure assessment, novel interventions, impact on lung diseases and economic burden in diverse European populations. The TackSHS Project. INSTITUT CATALA D'ONCOLOGIA tramitó un H2020: Exposure to secondhand tobacco smoke (SHS) has been classified as a Group 1 carcinogen (known human carcinogen) by the International Agency for Research on Cancer and has been shown to have adverse h...
2015-11-01 | Financiado
MoTriColor: Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON tramitó un H2020: Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease a...
2015-10-01 | Financiado
COHEAHR: Comparing health services interventions for the prevention of HPV-related cancer STICHTING VUMC tramitó un FP7: Important progress has been made in the field of HPV-disease prevention with the development and implementation of HPV vaccines and HPV DNA screening. In the CoheaHr project, the (cost-) effectiveness...
2013-11-01 | Financiado
FINDING CRC GENES: Identification of new colorectal cancer susceptibility genes INSTITUT CATALA D'ONCOLOGIA tramitó un FP7: The overall aim of this proposed project is to discovery new colorectal cancer (CRC) susceptibility genes to better understand the colorectal carcinogenesis process and improve the molecular diagnosis...
2013-06-17 | Financiado
STROMALIGN: Mechanisms and Targeting Stromal Contribution to Tumour Invasion and Metastasis INSTITUT CATALA D'ONCOLOGIA tramitó un FP7: Angiogenesis inhibition has proven to be a successful anti-cancer therapeutic approach and anti-angiogenic therapies are currently approved as standard therapy in several types of cancer for their cli...
2012-06-01 | Financiado
Cancer therapies: Use of adoptive T cell transfer in combination with oncolytic adenoviruses for cancer treatment INSTITUT CATALA D'ONCOLOGIA tramitó un FP7: Metastatic cancer remains an incurable disease in the majority of cases and thus development of novel treatment strategies is required. Adoptive T cell therapy is a promising therapy for patients with...
2011-05-01 | Financiado
PREHDICT: health-economic modelling of PREvention strategies for Hpv-related Diseases in European CounTries STICHTING VU tramitó un FP7: The goals of the PREHDICT study are to determine prerequisites and strategies for vaccination in European countries and to predict the impact of vaccination on screening programmes. To achieve these g...
2010-05-01 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.